Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis.
about
Treatment of patients with type 2 diabetes and non-alcoholic fatty liver disease: current approaches and future directionsClinical assessment of hepatic de novo lipogenesis in non-alcoholic fatty liver diseaseA Review of Western and Traditional Chinese Medical Approaches to Managing Nonalcoholic Fatty Liver Disease.Novel GLP-1 Analog Supaglutide Reduces HFD-Induced Obesity Associated with Increased Ucp-1 in White Adipose Tissue in Mice.Treatment of Nonalcoholic Fatty Liver Disease (NAFLD) in patients with Type 2 Diabetes Mellitus.Current and upcoming pharmacotherapy for non-alcoholic fatty liver disease.The Subtle Balance between Lipolysis and Lipogenesis: A Critical Point in Metabolic Homeostasis.An update on non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in Asia.Non-alcoholic fatty liver disease and diabetes.Bile acids and nonalcoholic fatty liver disease: Molecular insights and therapeutic perspectives.Review article: novel methods for the treatment of non-alcoholic steatohepatitis - targeting the gut immune system to decrease the systemic inflammatory response without immune suppression.Therapeutic application of GPR119 ligands in metabolic disorders.Review article: new treatments in non-alcoholic fatty liver disease.Novel antidiabetic medications for non-alcoholic fatty liver disease with type 2 diabetes mellitus.Novel Pharmacotherapy Options for NASH.Non-alcoholic fatty liver disease in 2016.Hepatogenous diabetes: Is it time to separate it from type 2 diabetes?Pharmacological management of nonalcoholic fatty liver disease in type 2 diabetes.C/EBP homologous protein modulates liraglutide-mediated attenuation of non-alcoholic steatohepatitis.Exenatide decreases liver fat content and epicardial adipose tissue in patients with obesity and type 2 diabetes: a prospective randomized clinical trial using magnetic resonance imaging and spectroscopy.Liraglutide improves liver microvascular dysfunction in cirrhosis: Evidence from translational studies.Antibody-Directed Glucocorticoid Targeting to CD163 in M2-type Macrophages Attenuates Fructose-Induced Liver Inflammatory Changes.Treatment options for alcoholic and non-alcoholic fatty liver disease: A review.Comparative effects of liraglutide 3 mg vs structured lifestyle modification on body weight, liver fat and liver function in obese patients with non-alcoholic fatty liver disease: A pilot randomized trial.Is It Time to Change the Type 2 Diabetes Treatment Paradigm? Yes! GLP-1 RAs Should Replace Metformin in the Type 2 Diabetes Algorithm.Nonalcoholic Fatty Liver Disease as a Nexus of Metabolic and Hepatic Diseases.The Asia-Pacific Working Party on Non-alcoholic Fatty Liver Disease guidelines 2017-Part 2: Management and special groups.Effect of exenatide on postprandial glucose fluxes, lipolysis, and ß-cell function in non-diabetic, morbidly obese patients.MECHANISMS IN ENDOCRINOLOGY: Diabetic cardiomyopathy: pathophysiology and potential metabolic interventions state of the art review.A novel glucagon-like peptide 1/glucagon receptor dual agonist improves steatohepatitis and liver regeneration in mice.SIRT1/HSF1/HSP pathway is essential for exenatide-alleviated, lipid-induced hepatic endoplasmic reticulum stress.Targeting GLP-1 receptor trafficking to improve agonist efficacy.Exenatide improves both hepatic and adipose tissue insulin resistance: A dynamic positron emission tomography study.Exenatide Delays the Progression of Nonalcoholic Fatty Liver Disease in C57BL/6 Mice, Which May Involve Inhibition of the NLRP3 Inflammasome through the Mitophagy Pathway.Pathogenesis of Nonalcoholic Steatohepatitis and Hormone-Based Therapeutic ApproachesFuture Perspectives on GLP-1 Receptor Agonists and GLP-1/glucagon Receptor Co-agonists in the Treatment of NAFLD
P2860
Q26751258-33B3644B-C353-4DBF-BD4A-B061A068D45EQ28072381-E99765C4-9D09-44A2-A2B5-B74AD34A945AQ28074377-FC69E1F1-84A4-490D-B366-82C509EB1724Q33679277-5BAB662F-EEE9-4705-A7BF-866F39AC77B5Q33802278-69E7BA25-1244-43D1-A2EF-4E20E39072C9Q34540703-75A557AD-4384-4F0D-9D12-88F609DDCA02Q36329899-1E2C8385-F435-4344-883C-43804374E830Q36405031-5E2B85B9-3576-4B04-BD92-5C683F6107A9Q37091659-CFF161F9-2E7E-478B-975F-3D58979704C8Q37538343-429EB331-A864-4C29-9E65-F1A6DD81D1DCQ37563673-9F023825-10FE-44F5-AAEC-0F3475A3CC54Q38655382-10AC4538-F998-4C8A-84BE-E108A2326F54Q38662765-807F8677-94D6-474B-8BDA-DF4DE748DB01Q38778064-FDB247D7-0F27-4CC3-8AB6-918967E4C62BQ38784790-EB460CD2-402E-4068-AEAF-E1C4725F7103Q38932554-081F6122-3270-4E16-A34D-7C14CC1CB578Q39036315-F8434499-5ADD-4A37-AC81-8CB48EE5AC53Q39170225-D8DAB111-8FB7-4D31-819A-BBC8FA5B4F01Q39726227-FB222745-F59E-4EF1-8CF4-963967C199D8Q39829216-8AFB8C94-2349-4B2B-B128-139D7EDEB541Q42206856-559FC1E0-7840-4053-818C-D5F958D3A255Q42284206-9AFE15E5-F581-4DCA-99CE-732C78002C86Q42695159-BE60F9A4-E003-484E-8981-4BFEF4AB6DF1Q47213563-BCD000F3-C780-4B63-96DA-C4355781C8ADQ47755876-A8A5F353-913C-4665-8716-1366E7E1FDE0Q47779219-26F2CF46-7C6F-4DD1-8371-B99599FB1B1DQ48152092-D419521E-D468-481F-A9E7-127AB7D43E5CQ48190910-A923ADCD-904A-482D-B984-516FCC02A7D0Q50026688-2AA7357A-1B68-44BA-BECD-F5C2B4937F13Q50222903-AE75B1A6-AE92-482A-B2CD-D593E3147B42Q51036933-4B030889-30C6-4E0D-9250-C7A92DB082A0Q53281306-AD20517F-626C-4C3D-8484-06E26422E4C2Q53964243-0A3A824E-FECD-42AB-8136-8FE2152E75E4Q55058152-8E7794C0-81EF-465B-A7C6-611DC8F4AC86Q58705640-0D2685E1-13D3-4181-859A-1FDF6218F694Q59136513-13633BD6-15BF-44AF-B5B4-18AE6EFC10A6
P2860
Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis.
@ast
Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis.
@en
type
label
Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis.
@ast
Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis.
@en
prefLabel
Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis.
@ast
Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis.
@en
P2093
P2860
P50
P1476
Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis
@en
P2093
Diana Hull
Jinglei Yu
Maryam Nasiri
Stephen C Gough
P2860
P304
P356
10.1016/J.JHEP.2015.08.038
P50
P577
2015-09-21T00:00:00Z